KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.

Won Ki Lee, Tien Y Wong, Shih-Jen Chen, Xiaodong Sun, Chui Ming Gemmy Cheung, Rufino Silva, Federico Ricci, Xin Zhang, Tobias Machewitz, Andrea Schulze, Ursula M Schmidt-Ott, Min Zhao, Zoran Hasanbasic, Sergio Leal, Tomohira Iida, PULSAR Study Investigators

JAMA Ophthalmol 144(2) 129-137

PMID41411005
PMCIDPMC12921519
DOI10.1001/jamaophthalmol.2025.5098
发表日期2025-12-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:非 KM 图;Figure 3.:森林图/亚组分析图;Figure 4.:非 KM 图。
摘要

摘要

IMPORTANCE: In the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) phase 3 randomized clinical trial, treatment with aflibercept, 8 mg, demonstrated noninferior (4-letter margin) best-corrected visual acuity (BCVA) gains vs aflibercept, 2 mg, in participants with neovascular age-related macular degeneration (nAMD). This post hoc subgroup analysis evaluated clinical outcomes in participants with polypoidal choroidal vasculopathy (PCV). OBJECTIVE: To compare the efficacy and safety of aflibercept, 8 mg vs 2 mg, monotherapy among participants with PCV in the PULSAR trial. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc subgroup analysis of the PULSAR randomized clinical trial. The setting included hospitals and clinics in 12 countries where indocyanine green angiography (ICGA) was performed to identify PCV. Included were a subgroup of adults with nAMD enrolled in the PULSAR trial with ICGA-confirmed PCV. Study data were analyzed from August 2020 to July 2022. INTERVENTIONS: Participants were randomly assigned 1:1:1 to aflibercept, 8 mg, every 12 weeks or 16 weeks, or aflibercept, 2 mg, every 8 weeks, each after 3 initial monthly doses. From week 16, dosing intervals in the treatment arms receiving 8 mg every 12 weeks and every 16 weeks were shortened if predefined disease activity criteria were met at prespecified visits. MAIN OUTCOMES AND MEASURES: Least-squares (LS) mean change in BCVA from baseline at week 48. RESULTS: A total of 139 participants were included in this analysis. ICGA-confirmed PCV was present in 44 participants in the treatment group receiving aflibercept, 8 mg, every 12 weeks (mean [SD] age, 72.2 [8.1] years; 50% male), 41 participants receiving 8 mg every 16 weeks (mean [SD] age, 73.2 [8.7] years; 63% male), and 54 participants receiving 2 mg every 8 weeks (mean [SD] age, 72.6 [8.2] years; 69% male). Mean baseline BCVA letter score (approximate Snellen) was 56.3 (20/80), 60.1 (20/63), and 57.6 (20/80), respectively, with 41, 37, and 51 participants completing week 48 and receiving a mean (SD) of 6.1 (0.4), 5.1 (0.5), and 7.0 (0.2) injections, including 68 of 78 (87%) treated with aflibercept, 8 mg, who maintained dosing intervals of 12 weeks or longer. In the treatment arms receiving aflibercept, 8 mg, every 12 and 16 weeks and aflibercept, 2 mg, every 8 weeks, LS mean BCVA change from baseline at week 48 was +9.5, +8.4, and +9.1 letters, respectively (estimated difference, 0.40; 95% CI, -4.4 to 5.2 letters for 8 mg every 12 weeks vs 2 mg every 8 weeks; -0.7; 95% CI, -4.6 to 3.2 letters for 8 mg every 16 weeks vs 2 mg every 8 weeks), and polypoidal lesions were absent in 37%, 47%, and 38% of participants, respectively, who completed week 48. CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the PULSAR randomized clinical trial in participants with PCV demonstrated similar visual and anatomic outcomes with aflibercept, 8 mg vs 2 mg, as administered in this trial, supporting the use of aflibercept, 8 mg, as an alternative monotherapy for PCV. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04423718.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Disposition in the PCV Subgroup Analysis of the PULSAR Randomized Clinical Trial ICGA indicates indocyanine green angiography; PCV, polypoidal vasculopathy; PULSAR, Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye. a Australia, n = 15; Austria, n = 7; France, n = 2; Italy, n = 22; Japan, n = 70; Latvia, n = 2; mainland China, n = 65; Singapore, n = 1; South Korea, n = 25; Spain, n = 3; Switzerland, n = 3; and the US, n = 77; PCV status could not be graded in 3 participants who underwent ICGA testing. b Presence of polypoidal lesions or branching neovascular networks.
非 KM Figure
Figure 2.Change in BCVA and Absolute CST Over 48 Weeks of Aflibercept Treatment in Participants With PCV A, LS means generated for the FAS using mixed model for repeated measurements (see Methods for details). B, FAS (observed cases before intercurrent events). BCVA indicates best-corrected visual acuity; CST, central subfield retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; LS, least squares; PCV, polypoidal choroidal vasculopathy; 2q8, aflibercept 2 mg every 8 weeks after 3 initial monthly doses; 8q12, aflibercept 8 mg every 12 weeks after 3 initial monthly doses; 8q16, aflibercept 8 mg every 16 weeks after 3 initial monthly doses.
非 KM Figure
Figure 3.Proportion of Participants in the PCV Subgroup Treated With Aflibercept, 8 mg, Who Maintained or Shortened Their Assigned Dosing Intervals Based on Predefined DRM Criteria Through Week 48 Data are for participants in the FAS who completed week 48; values may not add up to 100% due to rounding. DRM indicates dose regimen modification; FAS, full analysis set; PCV, polypoidal choroidal vasculopathy; 8q12, assigned aflibercept 8 mg every 12 weeks at randomization; 8q16, assigned aflibercept 8 mg every 16 weeks at randomization; Q8, dosing interval of every 8 weeks; Q12, dosing interval of every 12 weeks; Q16, dosing interval of every 16 weeks.
非 KM Figure
Figure 4.Proportion of Participants With PCV With Any Polypoidal Lesions or Active Polypoidal Lesions After 48 Weeks of Aflibercept, 8 mg and 2 mg, Treatment Data are for participants in the full analysis set who completed week 48. All proportions were calculated based on the number of participants who underwent assessment. Polypoidal lesions were classified as being present, absent, or questionable according to participants’ indocyanine green angiography results. Participants with inactive polypoidal lesions were defined as those with no polypoidal lesions present or as those with polypoidal lesions present but both intraretinal fluid and subretinal fluid were known to be absent. 2q8 indicates aflibercept 2 mg every 8 weeks after 3 initial monthly doses; 8q12, aflibercept 8 mg every 12 weeks after 3 initial monthly doses; 8q16, aflibercept 8 mg every 16 weeks after 3 initial monthly doses.
非 KM Figure